Strain Profile
Save
Limosilactobacillus reuteri ATCC PTA 6475
◔
Human-origin
Where this strain was first isolated, curated from the literature and culture-collection catalogs. It describes provenance only — not suitability, and not benefit.
How we classify this →
Sequenced
Whether a public genome assembly is linked for this strain. Without one the genome screens cannot run. It is not a verdict on the organism.
How we classify this →
Public genome assembly available
Limosilactobacillus reuteri ATCC PTA-6475 is a human-origin strain that has been studied for gut barrier function, immune modulation, and as a potential adjunct during Helicobacter pylori eradication therapy. A 2024 randomized controlled trial examined this strain alone and in combination with L. reuteri DSM 17938 in patients with diarrhea-predominant irritable bowel syndrome, examining gut barrier markers and symptoms. In vitro research has documented that the strain produces folate (vitamin B9) via a specific metabolic pathway, and has examined the strain's interaction with intestinal epithelial cells in the presence of enterotoxigenic E. coli. The evidence base includes both in vitro mechanistic work and small human studies. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 65 body-system-tagged papers that concern each system. Research coverage, not measured effect.
+1 more systems
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 24 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
74 papers reference this strain in the probiotic database.
Match confidence
How strongly this paper was matched to this strain when the corpus was linked. It orders the list — it says nothing about the study's quality or its findings.
How we classify this →
2026
META_ANALYSIS
2026
ANIMAL
2025
OBSERVATIONAL
2025
ANIMAL
2025
IN_VITRO
2025
IN_VITRO
2025
IN_VITRO
2025
OBSERVATIONAL
2025
OBSERVATIONAL
2024
RCT
2024
RCT
2024
RCT
2024
ANIMAL
2024
ANIMAL
2024
IN_VITRO
2024
ANIMAL
2024
RCT
2023
ANIMAL
2022
RCT
2021
WGS
Browse all 74 papers →
Limosilactobacillus reuteri DSM 17938 and PTA 6475 as adjunct in Helicobacter pylori therapy: Systematic review and meta-analysis
· World Journal of Gastroenterology
Social and neuroendocrine phenotypes reprogrammed by endocrine-disrupting chemicals can be mitigated by Limosilactobacillus reuteri modulation of the gut microbiome–thyroid–oxytocin axis
· bioRxiv (Cold Spring Harbor Laboratory)
Optimizing the Routine Use of Clinical Guidelines by Addition of Supplements (Probiotics and/or Bismuth) to Helicobacter pylori Eradication Protocols in a Clarithromycin Resistant and Tetracycline/Bismuth Naive Area: A Real-World Data Retrospective Analysis of 402 Cases (2016–24) in a Single Gastroenterology Unit
· Antibiotics
Maternal L. Reuteri Rescues Offspring ASD-Like Behavior and Altered Thyroid Hormone Target Transcripts in Oxytocin Neurons in an Environmental Mouse Model of Autism
· Physiology
Limosilactobacillus reuteri promotes the expression and secretion of enteroendocrine‐ and enterocyte‐derived hormones
· The FASEB Journal
Strain-specific modulation of IgA induction by Limosilactobacillus reuteri 2310
· The Journal of Immunology
Inhibitory potential of probiotic strains against pathogens associated withosteomyelitis of the jaws: a quantitative MIC and MBC analysis
· Cellular and Molecular Biology
Optimizing the Routine Use of Clinical Guidelines by Addition of Supplements (Probiotics and/or Bismuth) to Helicobacter pylori Eradication Protocols in a Clarithromycin Resistant and Tetracycline/Bismuth Naive Area: A Real-World Data Retrospective Analys of 402 Cases (2016-24) in a Single Gastroenterology Unit
· Preprints.org
Effect of probiotic Limosilactobacillus reuteri on a serum sex-hormone- and metabolic-syndrome-related health evaluation: a single-arm open-label pilot study
· Bioscience of Microbiota Food and Health
Limosilactobacillus reuteri 6475 and Prevention of Early Postmenopausal Bone Loss
· JAMA Network Open
Effects of probiotic supplementation on testosterone levels in healthy ageing men: A 12-week double-blind, placebo-controlled randomized clinical trial
· Contemporary Clinical Trials Communications
The effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone and in combination with L. reuteri DSM 17938 on gut barrier function, immune markers, and symptoms in patients with IBS-D—An exploratory RCT
· PLoS ONE
Maternal Limosilactobacillus reuteri rescues social and emotional recognition behavior in an environmental mouse model of autism
· Physiology
Heat-killed Limosilactobacillus reuteri ATCC PTA 6475 prevents bone loss in ovariectomized mice: A preliminary study
· PLoS ONE
Limosilactobacillus reuteri promotes the expression and secretion of enteroendocrine- and enterocyte-derived hormones
· bioRxiv (Cold Spring Harbor Laboratory)
Maternal probiotic supplementation protects against PBDE-induced developmental, behavior and metabolic reprogramming in a sexually dimorphic manner: Role of gut microbiome
· Archives of Toxicology
Limosilactobacillus reuteri DSM 17938 and ATCC PTA 6475 for the treatment of moderate to severe irritable bowel syndrome in adults: a randomized controlled trial
· Frontiers in Gastroenterology
The beneficial effects of simultaneous supplementation of Lactobacillus reuteri and calcium fluoride nanoparticles on ovariectomy-induced osteoporosis
· BMC Complementary Medicine and Therapies
One-year supplementation with Lactobacillus reuteri ATCC PTA 6475 counteracts a degradation of gut microbiota in older women with low bone mineral density
· npj Biofilms and Microbiomes
Genome-scale insights into the metabolic versatility of Limosilactobacillus reuteri
· BMC Biotechnology
Discussion
Be the first to comment.
Sign in to join the discussion.
No comments yet.
Citations
Selected papers that name this strain.
-
[1]
Source →Limosilactobacillus reuteri DSM 17938 and PTA 6475 as adjunct in Helicobacter pylori therapy: Systematic review and meta-analysis· World Journal of Gastroenterology · 2026
-
[2]
PMID 42539130 →Social and neuroendocrine phenotypes reprogrammed by endocrine-disrupting chemicals can be mitigated by Limosilactobacillus reuteri modulation of the gut microbiome–thyroid–oxytocin axis· bioRxiv (Cold Spring Harbor Laboratory) · 2026
-
[3]
PMID 39485760 →The effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone and in combination with L. reuteri DSM 17938 on gut barrier function, immune markers, and symptoms in patients with IBS-D—An exploratory RCT· PLoS ONE · 2024
-
[4]
PMID 38770015 →Effects of probiotic supplementation on testosterone levels in healthy ageing men: A 12-week double-blind, placebo-controlled randomized clinical trial· Contemporary Clinical Trials Communications · 2024
-
[5]
PMID 38865129 →Limosilactobacillus reuteri 6475 and Prevention of Early Postmenopausal Bone Loss· JAMA Network Open · 2024
-
[6]
Source →Heat-killed Limosilactobacillus reuteri ATCC PTA 6475 prevents bone loss in ovariectomized mice: A preliminary study· PLoS ONE · 2024
-
[7]
PMID 41821785 →Limosilactobacillus reuteri DSM 17938 and ATCC PTA 6475 for the treatment of moderate to severe irritable bowel syndrome in adults: a randomized controlled trial· Frontiers in Gastroenterology · 2024
-
[8]
PMID 36261538 →One-year supplementation with Lactobacillus reuteri ATCC PTA 6475 counteracts a degradation of gut microbiota in older women with low bone mineral density· npj Biofilms and Microbiomes · 2022
-
[9]
PMID 33947195 →Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori· Revista Española de Enfermedades Digestivas · 2021
-
[10]
PMID 33869994 →Metabolic Alterations in Older Women With Low Bone Mineral Density Supplemented With Lactobacillus reuteri· JBMR Plus · 2021